Last edition
News about "Annamycin "
Moleculin Reports Encouraging Interim Phase 2/3 Data for Annamycin in Relapsed or Refractory AML
Moleculin Biotech has reported encouraging preliminary blinded data from its pivotal Phase 2/3 MIRACLE trial, with Annamycin plus cytarabine achieving a 37 percent composite complete remission rate in relapsed or refractory acute myeloid leukaemia.
Annamycin | 03/08/2026 | By News Bureau
Moleculin Launches Grant-Funded Study of Annamycin for Pancreatic Cancer at UNC-Chapel Hill
Moleculin has initiated a grant-funded preclinical programme at the University of North Carolina at Chapel Hill to evaluate Annamycin in pancreatic cancer, including its use alongside novel therapeutic agents and modalities. Early studies suggest Annamycin may effectively target key drivers of the disease.
Annamycin | 15/11/2025 | By Dineshwori | 221
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy